Answer
Piqray (alpelisib), combined with fulvestrant, is indicated for postmenopausal women and men with HR-positive, HER2-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine-based therapy.
Sources for this answer
- Piqray 50 mg, 150 mg and 200 mg film-coated tabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 12Document updated
Sources checked